This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Statin treatment and diabetes risk

Authoring team

A meta-analysis into the risk of diabetes associated with statin use has been undertaken (1):

  • statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials
  • meta-regression showed that risk of development of diabetes with statins was highest in trials with older participants, but neither baseline body-mass index nor change in LDL-cholesterol concentrations accounted for residual variation in risk
  • treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes.

Statin therapy in adult women: risk of diabetes versus cardiovascular benefit

  • review of the literature indicates that the cardiovascular benefits of statins appear to outweigh the risk for statin-related diabetes (2)

NICE have stated "..Do not stop statins because of an increase in blood glucose level or HbA1c.."

In the REPRIEVE trial (randomized trial to prevent vascular events in HIV) (4):

  • trial was stopped early for efficacy after a median follow-up of 5.1 years
  • participants with at least 3 diabetes mellitus risk factors (vs. no risk factors) had increased risk for diabetes mellitus in each treatment group (incidence rate, 3.24 per 100 person-years [PY] vs. 0.34 per 100 PY [pitavastatin] and 2.66 per 100 PY vs. 0.27 per 100 PY [placebo])
  • incidence of diabetes mellitus was highest in South Asia. In adjusted analyses, high body mass index, prediabetes, and metabolic syndrome components were strongly associated with new-onset DM (all P < 0.005)
  • study authors concluded that:
    • metabolic risk factors, including prediabetes and obesity, contributed to new-onset diabetes in statin- and placebo-treated participants.
    • a clinically significant effect of pitavastatin on diabetes was seen primarily among those with multiple risk factors for diabetes at entry

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.